Premier's ProvideGx Program to Make the First FDA-Approved Version of Cysteine Hydrochloride Available to Providers
July 02, 2019
July 02, 2019
CHARLOTTE, North Carolina, July 2 -- Premier, a healthcare improvement company, issued the following news release:
Premier Inc. (NASDAQ: PINC), through its ProvideGx(TM) program, is now supplying cysteine hydrochloride injection to providers, a critical drug for pediatric and adult patients that require total parenteral nutrition (TPN). Cysteine hydrochloride has been in shortage in the U.S. since 2015.
This FDA-approved New Drug Application (NDA) for cysteine hydrochlo . . .
Premier Inc. (NASDAQ: PINC), through its ProvideGx(TM) program, is now supplying cysteine hydrochloride injection to providers, a critical drug for pediatric and adult patients that require total parenteral nutrition (TPN). Cysteine hydrochloride has been in shortage in the U.S. since 2015.
This FDA-approved New Drug Application (NDA) for cysteine hydrochlo . . .